Literature DB >> 15657030

Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions.

Ping-Yee Law1, Laurie J Erickson-Herbrandson, Qin Q Zha, Jon Solberg, Ji Chu, Aili Sarre, Horace H Loh.   

Abstract

Homo- and heterodimerization of the opioid receptors with functional consequences were reported previously. However, the exact nature of these putative dimers has not been identified. In current studies, the nature of the heterodimers was investigated by producing the phenotypes of the 1:1 heterodimers formed between the constitutively expressed mu-opioid receptor (MOR) and the ponasterone A-induced expression of delta-opioid receptor (DOR) in EcR293 cells. By examining the trafficking of the cell surface-located MOR and DOR, we determined that these two receptors endocytosed independently. Using cell surface expression-deficient mutants of MOR and DOR, we observed that the corresponding wild types of these receptors could not rescue the cell surface expression of the mutants, whereas the antagonist naloxone could. Furthermore, studies with constitutive or agonist-induced receptor internalization also indicated that MOR and DOR endocytosed independently and could not "drag in" the corresponding wild types or endocytosis-deficient mutants. Additionally, the heterodimer phenotypes could be eliminated by the pretreatment of the EcR293 cells with pertussis toxin and could be modulated by the deletion of the RRITR sequence in the third intracellular loop that is involved in the receptor-G protein interaction and activation. These data suggest that MOR and DOR heterodimerize only at the cell surface and that the oligomers of opioid receptors and heterotrimeric G protein are the bases for the observed MOR-DOR heterodimer phenotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15657030     DOI: 10.1074/jbc.M500171200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Agonists at the δ-opioid receptor modify the binding of µ-receptor agonists to the µ-δ receptor hetero-oligomer.

Authors:  N Kabli; N Martin; T Fan; T Nguyen; A Hasbi; G Balboni; B F O'Dowd; S R George
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 2.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization.

Authors:  G Milligan
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

4.  Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.

Authors:  Tingyou Li; Kimitaka Shiotani; Anna Miyazaki; Yuko Tsuda; Akihiro Ambo; Yusuke Sasaki; Yunden Jinsmaa; Ewa Marczak; Sharon D Bryant; Lawrence H Lazarus; Yoshio Okada
Journal:  J Med Chem       Date:  2007-05-12       Impact factor: 7.446

Review 5.  Membrane functional organisation and dynamic of mu-opioid receptors.

Authors:  André Lopez; Laurence Salomé
Journal:  Cell Mol Life Sci       Date:  2009-03-20       Impact factor: 9.261

6.  Peripheral δ-opioid receptors attenuate the exercise pressor reflex.

Authors:  Anna K Leal; Katsuya Yamauchi; Joyce Kim; Victor Ruiz-Velasco; Marc P Kaufman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-08-09       Impact factor: 4.733

Review 7.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

8.  Cell surface targeting of mu-delta opioid receptor heterodimers by RTP4.

Authors:  Fabien M Décaillot; Raphael Rozenfeld; Achla Gupta; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-03       Impact factor: 11.205

9.  Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia.

Authors:  L Gendron; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-10-05       Impact factor: 3.590

10.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.